Navigation Links
MS Patients More Compliant with Medications When Managed by Specialty Pharmacy, According to HealthCore Study Presented at ISPOR
Date:5/19/2009

Study reports MS medication possession ratio of 86 percent for specialty pharmacy members

ORLANDO, Fla., May 19 /PRNewswire/ -- Multiple sclerosis patients managed by a specialty pharmacy program were more compliant with medication, and had a lower risk of being hospitalized for their disease than those who were not managed by a specialty pharmacy program, according to a study completed by HealthCore, Inc.

HealthCore researcher Jingbo Yu presented the study today at the International Society of Pharmacoeconomic and Outcomes Research 14th Annual International Meeting in Orlando, Fla. The retrospective study analyzed medical and pharmacy claims data.

The HealthCore study compared 3,055 patients managed by PrecisionRx Specialty Solutions to 807 patients who were not part of a specialty pharmacy-managed group over a period of one year. PrecisionRx provided patient education materials, regularly scheduled nurse calls and refill reminders to its members.

The study showed that those in the managed group had a 47 percent lower risk of being hospitalized to treat conditions associated with MS compared to the non-managed group.

Average overall MS-related total cost of care for one year was $20,105 for the managed group versus $16,857 for the non-managed group. The difference was driven by improved persistence with medications. Over time, the average MS-related medical cost decreased $270 among the managed patients, while it increased $1,245 among the un-managed group.

The study showed that the overall cost of care among the group managed by PrecisionRx Specialty Solutions, a subsidiary of WellPoint Inc., was higher because these members adhered better to their MS medication, which is costly. Reduced short-term disability costs, improved presenteeism and productivity were not directly assessed in the study, but likely are significant due to the significantly decreased utilization of medical services.

"Outcomes are clearly better for patients when they receive more sophisticated support and education that is encouraging them to stay compliant with their medication," said Dr. Joseph Singer, vice president of clinical affairs for HealthCore, the research outcomes subsidiary for WellPoint Inc. "It's well-documented that these drugs keep patients healthier and functioning at a higher level for a much longer period of time than if they weren't taking these drugs, despite their common side effects."

Multiple sclerosis is a chronic and progressive inflammatory disease of the central nervous system that affects about 400,000 people in the United States. The medications currently available to treat MS are effective in reducing relapses but are associated with side effects that reduce their tolerability. Those patients managed by PrecisionRx achieved a length of continuous therapy over 290 days compared to 209 days by the non-managed group, which was statistically and clinically significant.

"Because MS drugs have significant side effects, the regularly scheduled nurse calls -- at three, six and then 12 months, can make a huge difference in how that member continues with therapy," said Tracy Nolan, vice president of PrecisionRx Specialty Solutions. "We develop relationships with members that open the door to them sharing with us issues they may have in being compliant. By knowing what those problems are, we can often help them figure out a solution."

About the study

A total of 3,862 patients were identified in the study with 79 percent managed and 21 percent non-managed. The median age was 46 years and the majority was female. More than one-third of the patients used Avonex as index medication, while others used Copaxone (31 percent), Rebif (17 percent), Betaseron (14 percent) and Tysabri (less than 1 percent).

About HealthCore

HealthCore, based in Wilmington, Del., is the clinical outcomes research subsidiary of WellPoint. HealthCore has a team of highly experienced researchers including physicians, biostatisticians, pharmacists, epidemiologists, health economists and other scientists who study the "real world" safety and effectiveness of drugs, medical devices and care management interventions. HealthCore offers insight on how to best use this data and communicates these findings to health care decision-makers to support evidence-based medicine, product development decisions, safety monitoring, coverage decisions, process improvement and overall cost-effective health care. For more information, go to www.healthcore.com.


'/>"/>
SOURCE WellPoint, Inc.; HealthCore
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. New Data Demonstrate RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment May Improve Health Outcomes and Reduce Hospitalizations in Patients with Schizophrenia
2. Two Targeted Therapies Likely Better Than One in Patients with Aggressive Lymphoma, Mayo Clinic Researchers Say
3. $1.5 million awarded for palliative care research to improve care of seriously ill patients
4. Patients reveal willingness to trade hands-on medical care for computer consultations
5. PRN Calls on Obama Lawyers to Stand Down in Their Drug War on Patients and Doctors
6. New Spray Could Benefit Cystic Fibrosis Patients
7. Large clinical trial finds pirfenidone may help lung function in IPF patients
8. 2-week course of sleep aid increases CPAP adherence in OSA patients at 6 months
9. Important Data Presented on Independent Predictors of Mortality in Patients With Idiopathic Pulmonary Fibrosis
10. Transplant patients have worse cancer outcomes, analysis shows
11. U.S. Study Shows Significant Improvement for Patients Suffering from Excessive Sweating with Topical Antiperspirant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/6/2016)... CA (PRWEB) , ... February 06, 2016 , ... With ... and easily add warm color grades to their footage. A LUT is a Lookup ... pixel's color to the corresponding color indicated by the table. By manipulating each pixel, ...
(Date:2/5/2016)... Bethpage, NY (PRWEB) , ... February 05, 2016 , ... ... florist-quality long-stem roses in a variety of colors, assortments and packaging. This staple for ... at any King Kullen location. , For Valentine’s Day, not only are long-stem ...
(Date:2/5/2016)... ... February 05, 2016 , ... The event is being held on April 7, ... Minneapolis, Minn. Triumph Over Parkinson’s will fund nearly $100,000 for research for the care ... with Parkinson’s disease and is the architect of this informative event to raise awareness ...
(Date:2/5/2016)... ... February 05, 2016 , ... Freed-Hardeman University President ... have signed a joint enrollment and degree completion agreement. The agreement, which ... baccalaureate degrees at FHU|Dickson. , The agreement allows students to be jointly ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... ... independent PROSHRED franchises from across the country gathered at the La Valencia Hotel ... top performers. PROSHRED Chicago was named the year’s most outstanding franchise, walking ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... Feb. 5, 2016  ivWatch, a medical devices company, is ... Award granted by Governor Terry McAuliffe,s office. ivWatch ... February 25th at an event to be held at the ... award honors professionals and business that have made significant contributions ... Logo - http://photos.prnewswire.com/prnh/20160205/330117LOGO ...
(Date:2/5/2016)... 2016 http://www.researchandmarkets.com/research/jsc97m/global ... "Global Musculoskeletal Partnering 2010-2016: Deal trends, ... their offering. --> http://www.researchandmarkets.com/research/jsc97m/global ... "Global Musculoskeletal Partnering 2010-2016: Deal trends, ... their offering. --> Research ...
(Date:2/5/2016)... , Feb. 5, 2016 Dehaier Medical ... or the "Company"), which develops, markets and sells ... China and international markets, ... which aims to concentrate the Company,s resources to ... respiratory business and to focus more on its ...
Breaking Medicine Technology: